Novo Nordisk (NVO) announced its higher dose Wegovy injection is available now in the U.S. nationwide. “This advancement builds on the many offerings for patients within the Wegovy label and opens up a new option for American adults living with obesity looking to lose weight and keep it off, along with diet and exercise,” the company said in a statement.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Updates Progress on 2026 DKK 15 Billion Share Buyback
- Mixed options sentiment in Novo Nordisk with shares down 0.39%
- Trump Trade: U.S. strengthens tariffs on steel, aluminum, copper imports
- Anthropic Finalizes $400 Million Takeover of AI Startup Coefficient Bio
- AZN, NVO, NVS: What Does Trump’s New 100% Tariff Mean for Pharma Giants?